disease 921 words KG: ent-dise-439cee73
Contents

Frontotemporal Dementia (FTD) Genetic Variants

Disease Info
InheritanceAutosomal dominant
Behavioral variant FTD (bvFTD)Personality and behavioral changes
Primary progressive aphasia (PPA)Language impairment
Major causal genesMAPT, GRN, C9orf72 (accounting for ~60% of familial FTD)
Other causal genesVCP, CHCHD10, TARDBP, FUS
Risk genesTMEM106B, APOE, ABCA7
MechanismsAltered splicing, reduced tau binding to microtubules, increased aggregation
PhenotypebvFTD, PPA, CBS
P301LMost common, causes early onset bvFTD
P301SAggressive phenotype
K369ICauses Lewy body pathology
Exon 10 mutationsLead to 3R/4R tau imbalance
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (20)

Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Cross-Seeding Prevention Strategy
Score: 0.69
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
Cryptic Exon Silencing Restoration
Score: 0.53
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
APOE-TREM2 Interaction Modulation
Score: 0.74
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
APOE Isoform Conversion Therapy
Score: 0.72
Lysosomal Positioning Dynamics Modulation
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
TREM2-Dependent Microglial Senescence Transition
Score: 0.58
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47

Related Analyses (12)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived

Related Experiments (16)

FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.